3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Phase 1/2
1
Status
Recruiting
3
Unknown
1
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
4
Neoplasm Metastasis
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Large-Cell, Anaplastic
2
Sexual Dysfunction, Physiological
1
Rare Tumor
1
Neuroblastoma
1
Lymphoma
1
Lung Diseases
1
Eunuchism
1
Erectile Dysfunction
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
pembrolizumab
49
Carboplatin
44
Magnetic Resonance Spectroscopy
40
Specimen Handling
39
Pemetrexed
35
Cisplatin
26
Blood Specimen Collection
25
durvalumab
17
Paclitaxel
17
osimertinib
15
Radiosurgery
15
Bevacizumab
15
Radiotherapy
14
Nivolumab
14
Gemcitabine
14
atezolizumab
13
Biopsy
13
Drug Therapy
12
Docetaxel
11
130-nm albumin-bound paclitaxel
11
Immunoglobulin G
10
X-Rays
9
Taxes
9
Standard of Care
9
Practice Guidelines as Topic
9
Educational Status
9
Disulfides
9
tislelizumab
8
Etoposide
8
Cetuximab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Lung Neoplasms
×
alectinib
×
Clear all
NCT06765109
2026-05-14
ALKAZAR
Nuvalent Inc.
Phase 3
Recruiting
450 enrolled
NCT05987644
2026-04-08
DURABLE
Hoosier Cancer Research Network
Phase 1/2
Recruiting
56 enrolled
NCT05525338
2024-05-13
ADAPT ALEC
University Medical Center Groningen
Phase 4
Recruiting
196 enrolled